Posted by SalArmy4me on August 26, 2001, at 23:35:31
In reply to Geodon and mania question, posted by anna on August 26, 2001, at 23:05:23
5. Keck, Paul E. Jr. MD. Ziprasidone in the Short-Term Treatment of Patients with Schizoaffective Disorder: Results from Two Double-Blind, Placebo-Controlled, Multicenter Studies. Journal of Clinical Psychopharmacology. 21(1):27-35, February 2001.
"In these studies, ziprasidone exerted a dose-dependent reduction in psychotic and affective symptoms in patients with schizoaffective disorder. Specifically, ziprasidone 160 mg/day produced significant improvement in the overall psychopathology as measured by reductions in mean BPRS total scores from baseline to endpoint compared with placebo. Ziprasidone 160 mg/day also produced significant improvement in BPRS core symptoms, BPRS manic symptoms, and CGI-S scores compared with placebo. At lower dosages, numerical but not statistically significant superiority of ziprasidone over placebo was evident for all efficacy variables except for CGI-S. On this variable, ziprasidone 120 mg/day produced significant improvement compared with placebo. Ziprasidone, at the doses studied, appeared to exert a more robust effect in the treatment of manic symptoms compared with depressive symptoms during the 4- or 6-week treatment periods studied. This finding was encouraging, given ziprasidone's theoretical potential for inducing mania because of its anti-depressant activity, which is likely associated with its 5-HT1A agonist, 5-HT2 antagonist, and reuptake inhibition of serotonin and norepinephreine.30 Ziprasidone was also associated with reductions in depressive symptoms from baseline to endpoint in both studies. Although these were consistently numerically greater than those associated with placebo (except at 80 mg/day), they were not statistically significant..."
poster:SalArmy4me
thread:76520
URL: http://www.dr-bob.org/babble/20010822/msgs/76524.html